HOME >> MEDICINE >> NEWS
Clarifying controversy in multiple sclerosis

Multiple sclerosis (MS) is a crippling autoimmune disease of the central nervous system (CNS) in which the protective nerve cell coating called myelin is damaged. Although uncontrolled CNS inflammation by immune cells called microglia (MG) and production of the protein TNF-alpha are considered important causes of demyelination and loss of nerve (neuron) function in MS, there is evidence to suggest that a controlled inflammatory response may actually restore damaged myelin and nerve function. Now, in a study appearing online on March 23 in advance of print publication in the April issue of the Journal of Clinical Investigation, researcher Michal Schwartz and colleagues at the Weizmann Institute of Science in Israel help clarify the controversy by reporting that it is the mechanism by which the MGs are activated that determines whether they are destructive or protective. Using both mouse and rat animal models of MS, the authors show that production by immune cells known as helper T cells of small amounts of a proinflammatory protein called IFN-gamma or production of an anti-inflammatory protein IL-4 could stimulate MGs to support nerve cell survival. In contrast, the researchers show that MGs fail to protect neurons when they are exposed to high doses of IFN-gamma, because high levels of IFN-gamma stimulate the MGs to produce TNF-alpha. The results demonstrate that the helper T cells can have direct control over MG action, stimulating them to either support or destroy nerve cell function through production of IL-4, and suggest that stimulation of MGs with IL-4 may help in MS clinical recovery.


'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
23-Mar-2006


Page: 1

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. IOM report should end nevirapine controversy, HIVMA says
3. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
4. University hospitals wins multiple national IT awards for electronic patient data bank
5. Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
6. Glucosamine-like supplement inhibits multiple sclerosis, type 1 diabetes
7. Testosterone may help men with multiple sclerosis
8. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
9. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
10. New GreeneChip identifies multiple pathogens rapidly and accurately
11. GreeneChip -- New diagnostic tool that rapidly and accurately identifies multiple pathogens

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clarifying controversy multiple sclerosis

(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results ... Navigant Center for Healthcare Research and Policy Analysis show widespread support for the ... said they agreed or strongly agreed that the controversial law passed in 2010 ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
(Date:8/3/2015)... August 3, 2015 /OFF ... Group LLC, PIV757417 The following release: "Biotech Advancements ... Drug Products & Treatments for Critical-Care Patients With ... time: 3 Aug 2015 12:30 GMT ... military surgical research and top-tier universities for identifying ...
(Date:8/3/2015)... Fla. , Aug. 3, 2015  Charleston ... initiation of its second clinical development program with ... candidate, CL-H1T.  CL-H1T contains fast-dissolving ... being developed as a treatment for migraine headache ... "Many patients with migraine headaches also ...
(Date:8/3/2015)... ZIONA, Israel , August 3, ... TASE: BVXV) today announced it received the statistical analysis of ... vaccine (M-001), administered in the BVX-005 phase II trial which ... future strains which did not exist at the time of ... (flu) strain that caused the epidemic in the ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
Cached News: